Keros Therapeutics Stock Forecast
NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 11.95 0.00%
KROS analyst consensus
Consensus (7 analysts)
buy
Avg. price target
$19.83+65.94%
- Strong buy 0
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Keros Therapeutics (2026-10-08), 4 rate the stock a buy or strong buy, 3 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $19.83, with a high estimate of $25.00 and a low estimate of $16.00. The average target implies upside of 65.9% from the current price of $11.95.
The spread between the highest and lowest targets is 56.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for KROS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 57% |
| Hold | 3 | 43% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $16.00 | +33.89% |
| Average target | $19.83 | +65.94% |
| High target | $25.00 | +109.21% |